 Home > Active Ingredient News > Antitumor Therapy > BMC Cancer: Eribulin improves overall survival after initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer

BMC Cancer: Eribulin improves overall survival after initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

lectins cancer

studies classification

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In prospective and retrospective studies, eribulin improved overall survival (OS) in patients with HER2-negative advanced breast cancer
(ABC) .

However, as first-line chemotherapy, the effect of eribulin on OS and the characteristics of patients with benefit are unclear

In prospective and retrospective studies, eribulin improved overall survival (OS) in patients with HER2-negative advanced breast cancer

The study included 301 patients with HER2-negative advanced breast cancer (ABC) treated at 3 institutions in Japan from January 2011 to December 2016
.

There were 172 eribulin-treated patients (119 estrogen receptor positive [ER+], 47 ER-, 6 unknown) and 129 untreated (92 ER+, 31 ER-, 6 unknown)

The study included 301 patients with HER2-negative advanced breast cancer (ABC) treated at 3 institutions in Japan from January 2011 to December 2016

Median follow-up was 21.

In multivariate analysis, ER-negative status (HR 1.
79; 95% CI: 1.
29-2.
48), bone metastases at the start of first-line chemotherapy (HR 1.
51; 95% CI 1.
10-2.
07), and liver metastases at the start of first-line chemotherapy (HR 1.
61; 95% CI: 1.
14-2.
28), disease-free interval <24 (HR: 1.
39; 95% CI: 1.
04-1.
87), perioperative anthracycline and/or taxane-based therapy (HR 1.
66; 95 % CI: 1.
23-2.
24) were all associated with worse OS
.

Therefore, we performed additional analyses of subgroups of patients receiving perioperative anthracycline and/or taxane therapy
.

There was no significant difference in median OS from the start of first-line chemotherapy between Eribulin and non-Eriblin groups (834 vs.

Therefore, we performed additional analyses of subgroups of patients receiving perioperative anthracycline and/or taxane therapy

In multivariate analysis, ER-negative status (HR 1.
99; 95% CI: 1.
14-3.
46), bone metastases at initiation of first-line chemotherapy (HR 3.
28; 95% CI: 1.
84-5.
82), disease-free interval <24 months ( HR 1.
80; 95% CI: 1.
04-3.
10), visceral metastases at the start of first-line chemotherapy (HR 3.
96; 95% CI: 1.
94-8.
08), and ≥3 sites of metastases at the start of first-line chemotherapy (HR 0.
55; 95% CI: 0.
30- 1.
00) OS dependent
.

In addition, treatment with eribulin in the later line had better OS than treatment without eribulin (HR 0.

In multivariate analysis, ER-negative status (HR 1.

Taken together, studies have shown that Eribulin improves overall survival after initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer
.

Studies have shown that Eribulin improves overall survival after the initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer

Original source:

Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M.
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
BMC Cancer.
2022 Jan 3;22( 1):31.
doi: 10.
1186/s12885-021-09137-0.
PMID: 34980019; PMCID: PMC8722338.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.